Cargando…
Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts
To explore mechanisms by which SGLT2 inhibitors protect diabetic hearts from heart failure, we examined the effect of empagliflozin (Empa) on the ultrastructure of cardiomyocytes in the noninfarcted region of the diabetic heart after myocardial infarction (MI). OLETF, a rat model of type 2 diabetes,...
Autores principales: | Mizuno, Masashi, Kuno, Atsushi, Yano, Toshiyuki, Miki, Takayuki, Oshima, Hiroto, Sato, Tatsuya, Nakata, Kei, Kimura, Yukishige, Tanno, Masaya, Miura, Tetsuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014462/ https://www.ncbi.nlm.nih.gov/pubmed/29932506 http://dx.doi.org/10.14814/phy2.13741 |
Ejemplares similares
-
Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020) -
Accuracy of flash glucose monitoring in insulin‐treated patients with type 2 diabetes
por: Sato, Tatsuya, et al.
Publicado: (2018) -
Reply to the comment of Hirota et al. on “Accuracy of flash glucose monitoring in insulin‐treated patients with type 2 diabetes”
por: Sato, Tatsuya, et al.
Publicado: (2019) -
Distinct impacts of sleep-disordered breathing on glycemic variability in patients with and without diabetes mellitus
por: Nakata, Kei, et al.
Publicado: (2017) -
Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats
por: Kimura, Yukishige, et al.
Publicado: (2019)